---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-007648"
form_type: "8-K"
ticker: "ABT"
cik: "0000001800"
company_name: "ABBOTT LABORATORIES"
filed_at: "2022-01-26T23:59:59+00:00"
generated_at: "2026-06-27T15:31:04.934594+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Abbott Q4 revenue $11.5B, adj EPS $1.32; FY2022 adj EPS guidance at least $4.70

## Summary
- Q4 2021 GAAP diluted EPS $1.11; adjusted diluted EPS $1.32; sales $11.5B (+7.2% reported, +7.7% organic).
- Full-year 2021 adjusted diluted EPS $5.21 (+42.7% YoY); total sales $43.1B (+24.5% reported).
- COVID-19 testing sales $2.3B in Q4, $7.7B full year; company distributed over 1.4 billion tests since pandemic began.
- FY2022 guidance: GAAP EPS at least $3.43, adjusted EPS at least $4.70; COVID testing sales forecast $2.5B.
- Quarterly dividend of $0.47 per share declared, payable Feb. 15, 2022; marks 50 consecutive years of dividend increases.

## SEC filing metadata
- accession: 0001104659-22-007648
- form_type: 8-K
- ticker: ABT
- cik: 0000001800
- company_name: ABBOTT LABORATORIES
- filed_at: 2022-01-26T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1800/000110465922007648/0001104659-22-007648-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1800/000110465922007648/tm224433d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-007648
- JSON: https://secwatch.observer/filing/0001104659-22-007648.json
- Plain text: https://secwatch.observer/filing/0001104659-22-007648.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.